Peter Boyd Biography and Net Worth

Peter Boyd joined the Company in August 2013 and now leads the Information Technology, Human Resource, and Communications functions for Aquestive. Prior to that, Mr. Boyd led the Company’s Operations and Value Delivery functions from April 2014 to May 2019. Mr. Boyd was the Company’s Vice President of Business Process at Aquestive from August 2013 until April 2014.

Prior to joining the Company, Mr. Boyd served as Senior Director of Operations for the Americas and APJ Regions at Hewlett-Packard Company. Throughout his 15-year career at Hewlett-Packard, Mr. Boyd held a variety of positions in business process improvement and operations.

Mr. Boyd received a BA in History from Wittenberg University and an MBA in Finance from Seton Hall University. He also received an MS in Management and Urban Policy Analysis from the New School University.

What is Peter E. Boyd's net worth?: The estimated net worth of Peter E. Boyd is at least $1.31 million as of March 10th, 2026. Boyd owns 338,509 shares of Aquestive Therapeutics stock worth more than $1,313,415 as of March 24th. This net worth approximation does not reflect any other assets that Boyd may own. Learn More about Peter E. Boyd's net worth.
How old is Peter E. Boyd?: Boyd is currently 58 years old. There are 4 older executives and 4 younger executives at Aquestive Therapeutics. The oldest executive at Aquestive Therapeutics is Ms. Lori J. Braender BSBA, Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary, who is 68 years old. Learn More on Peter E. Boyd's age.
How do I contact Peter E. Boyd?: The corporate mailing address for Boyd and other Aquestive Therapeutics executives is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. Aquestive Therapeutics can also be reached via phone at (908) 941-1900 and via email at [email protected]. Learn More on Peter E. Boyd's contact information.
Has Peter E. Boyd been buying or selling shares of Aquestive Therapeutics?: In the last ninety days, Peter E. Boyd has sold $124,324.38 in shares of Aquestive Therapeutics stock. Most recently, Peter E. Boyd sold 29,814 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a transaction totalling $124,324.38. Following the completion of the sale, the insider now directly owns 338,509 shares of the company's stock, valued at $1,411,582.53. Learn More on Peter E. Boyd's trading history.
Who are Aquestive Therapeutics' active insiders?: Aquestive Therapeutics' insider roster includes Daniel Barber (CEO), Peter Boyd (Insider), Lori Braender (Insider), Melina Cioffi (SVP), Ernest Jr (CFO), Cassie Jung (COO), Sherry Korczynski (Insider), Carl Kraus (Insider), and Alexander Schobel (Insider). Learn More on Aquestive Therapeutics' active insiders.
Are insiders buying or selling shares of Aquestive Therapeutics?: In the last year, insiders at the sold shares 15 times. They sold a total of 672,460 shares worth more than $3,342,230.34. The most recent insider tranaction occured on March, 10th when insider Peter E Boyd sold 29,814 shares worth more than $124,324.38. Insiders at Aquestive Therapeutics own 8.4% of the company. Learn More about insider trades at Aquestive Therapeutics.
Information on this page was last updated on 3/10/2026.

Peter E. Boyd Insider Trading History at Aquestive Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/10/2026	Sell	29,814	$4.17	$124,324.38	338,509
10/15/2025	Sell	10,000	$7.00	$70,000.00	268,323
9/26/2025	Sell	10,000	$6.30	$63,000.00	278,323
9/5/2025	Sell	15,000	$5.30	$79,500.00	288,323
6/14/2022	Buy	5,000	$0.81	$4,050.00	59,532
6/8/2022	Buy	2,293	$0.96	$2,201.28	54,532
8/12/2019	Buy	600	$3.81	$2,286.00
11/21/2018	Buy	200	$9.98	$1,996.00

Peter E. Boyd Buying and Selling Activity at Aquestive Therapeutics

Aquestive Therapeutics Company Overview

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Today's Range

Now: $3.88

$3.77

$3.91

50 Day Range

MA: $3.83

$2.95

$4.37

2 Week Range

Now: $3.88

$2.12

$7.55

Volume

1,537,372 shs

Average Volume

5,024,399 shs

Market Capitalization

$473.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Peter Boyd Biography and Net Worth

What is Peter E. Boyd's net worth?

How old is Peter E. Boyd?

How do I contact Peter E. Boyd?

Has Peter E. Boyd been buying or selling shares of Aquestive Therapeutics?

Who are Aquestive Therapeutics' active insiders?

Are insiders buying or selling shares of Aquestive Therapeutics?